Video
ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
ASCO 2022: Latest developments in mHSPC and mCRPC
Prof Heather Payne, Prof Kim Chi, Prof Laura-Maria Krabbe and Prof Kurt Miller
COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity i...
Dr Sumanta K. Pal - City of Hope Comprehensive Cancer Center, Duarte, USA
Safety follow-up of the randomized, phase 3 study DESTINY-Breast03
Dr Erika Hamilton - Sarah Cannon Research Institute, Tennessee, USA
ASCO 2022: Latest in EGFR positive NSCLC
Prof Benjamin Besse, Dr Anna Minchom, Dr Antonio Passaro and Dr Enriqueta Felip
Trastuzumab deruxtecan doubles PFS in metastatic breast cancer with low HER2 exp...
Dr Shanu Modi - Memorial Sloan Kettering Cancer Centre, Manhattan, USA
Comment:Trifluridine/tipiracil, bevacizumab + trifluridine/tipiracil provides be...
Dr Cathy Eng- Vanderbilt-Ingram Cancer Center, Nashville, USA
Comment: Phase 3 study shows HER2 therapy clinically meaningful for metastatic b...
Dr Jane Lowe Meisel- Winship Cancer Institute of Emory University, Georgia, USA
(RVd) ± , stem cell transplantation and R maintenance shows significance for new...
Dr Paul Richardson- Dana Farber Cancer Institute, Boston, USA
High-dose ifosfamide standard of care for recurrent and primary refractory ewing...
Dr Martin McCabe - University of Manchester, Manchester, England
Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM: Phase 3 D...
Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA
Trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil provides bene...
Dr Takayuki Yoshino - National Cancer Center Hospital East, Kashiwa, Japan
Single-agent PD-1 blockade as curative-intent treatment in mismatch repair-defic...
Dr Andrea Cercek - Memorial Sloan Kettering Cancer Centre, Manhattan, New York